Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
US9107926B2 · kind B2 · utility
23Cited by
10References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 2013 |
| Grant date | Aug 18, 2015 |
| Priority date | — |
| Expiry date | Jun 7, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.